What generalist deal databases miss in biotech

Generalist deal databases are good at a specific job: recording that a financing or an acquisition happened, with an amount and a date, across every industry. For most sectors that is enough. In life sciences it is the beginning of the question, not the answer.

The reason is structural. A generalist database files a company under an industry tag ("Biotechnology", maybe a sub-tag) and stops. But the things that determine whether a biotech deal is good live one level deeper, in dimensions these tools were never built to model.

The indication

Two oncology companies can be nothing alike. The disease a program targets sets its trial design, its endpoints, its competitive set, and its likely acquirer. An industry tag flattens all of that into one bucket. Without the indication as a first-class dimension, you cannot ask the questions that matter, and in biotech almost all of them start with the disease.

The mechanism and modality

How a drug works is not a keyword; it is the risk profile. Small molecule, antibody, ADC, RNA, gene therapy: each carries different development odds and different buyers. A landscape organized by mechanism is comparable. A landscape organized by industry tag is a list.

The clinical context

Financings do not happen in a vacuum; they happen around readouts. A round that closes just before a Phase 2 result means something different from one that closes just after. Generalist databases record the round but not the trial, so the single most important piece of context, where the science stood when the money moved, is missing.

The partnership structure

In life sciences, the deal is often not a round at all. It is a license, an option, a milestone-laden collaboration. "Is this asset already partnered with large pharma?" is a first-order question for any investor or BD team, and it is one a rounds-and-amounts database cannot answer.

Why it compounds

None of these gaps is fatal on its own. Together they mean the most useful biotech questions, like "Phase 2 assets in this indication, this mechanism, with no large-pharma partner", can't be asked directly. They become a keyword search followed by a week of manual work, which is exactly the work a purpose-built life sciences map should do for you.

That is the wager behind Terrane: model the dimensions that generalist tools skip (indication, mechanism, clinical stage, partnership status) and connect them, with a citation on every relationship. Same raw events; a very different question you get to ask.